Apathy syndrome in depressed patients previously treated with selective serotonin reuptake inhibitors

Petrova N.N.; Markin A.V.

doi:https://doi.org/10.17116/jnevro2020120011111

Close metadata

Recommended articles:

Identification of depression biomarkers: Prospects for use in clinical practice. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):51-55

Depression Anxiety Stress Scale (russian language version). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):103-107

Investigation of the relationship of individual characteristics of the brain bioelectrical activity with levels of mental stress, aggression, anxiety, and depression. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):108-117

Modern concepts of sleep disturbances associated with mental disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(6):7-12

Validation of the Snaith—Hamilton Pleasure Scale to assess anhedonia in patients with unipolar depression In Russia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7):110-121

Factors supporting chronic inflammation in mental illness. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8):7-15

Effect of polymorphic variants of the HTR2A gene on the effectiveness and safety of sertraline in patients with mixed anxiety-depressive disorder. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8):75-84

Gender characteristics of cardiovascular diseases psychosocial risk factors associations with sleep quality in an open urban population. Russian Journal of Preventive Medicine. 2025;(6):67-73

Dysfunctional pelvic pain in women. Russian Journal of Pain. 2025;(2):32-37

Psychodermatological aspects of psoriasis, current condition of problem. Russian Journal of Clinical Dermatology and Venereology. 2025;(4):403-411

Abstract:

This review of literature considers apathy syndrome induced by selective serotonin reuptake inhibitors (SSRI). Epidemiology and etiology of this phenomenon are not clear. Clinical features, diagnosis of apathy, differentiating and correlations between apathy and depression are presented. The possible mechanisms of onset and strategies of therapy of SSRI-induced apathy are discussed. It has been concluded that, despite the clinical evidence of the relationship between apathy and SSRI treatment, evidence-based research is needed.

Keywords:

apathy

depression

serotonin reuptake inhibitors

Authors:

Petrova N.N.

Saint-Petersburg State University, Saint-Petersburg, Russia

Markin A.V.

Department of anesthesiology and intensive care II, Petrovsky Russian Research Center for Surgery, Moscow, Russia

Close metadata

References:

Gould S, Friedman LF. Something startling is going on with antidepressant use around the world. Business Insider. 2016. Date of the access 5.2.19. URL: https://www.businessinsider.com/countries-largest-antidepressant-drug-users-2016-2
Sansone RA, Sansone LA. SSRI-induced indifference. Psychiatry (Edgmont). 2010;7(10):14.
Barnhart WJ, Makela EH, Latocha MJ. SSRI-induced apathy syndrome: a clinical review. J Psychiatr Pract. 2004;10:196-199.
Hoehn-Saric R, Lipsey JR, McLeod DR. Apathy and indifference in patients on fluvoxamine and fluoxetine. J Clin Psychopharmacol. 1990;10:343-345.
Hoehn-Saric R, Harris GJ, Pearlson GD, Cox CS, Machlin SR, Camargo EE. A fluoxetine-induced frontal lobe syndrome in an obsessive compulsive patient. J Clin Psychiatry. 1991;52:131-133.
George MS, Trimble MR. A fluvoxamine-induced frontal lobe syndrome in a patient with comorbid Gilles de la Tourette’s syndrome and obsessive compulsive disorder. Response by R Hoehn-Saric. J Clin Psychiatry. 1992;53:379-380.
Bolling MY, Kohlenberg RJ. Reasons for quitting serotonin reuptake inhibitor therapy: paradoxical psychological side effects and patient satisfaction. Psychother Psychosom. 2004;73:380-385.
Bertschy G, Baumann P. Vulnerability to fluoxetine-induced indifference syndrome among opiate addicts: a case report. Biol Psychiatry. 1995;38:404-406.
Aydemir EO, Aslan E, Yazici MK. SSRI Induced Apathy Syndrome. Psychiatry and Behavioral Sciences. 2018;8(2):63-70.
Fava M, Graves LM, Benazzi F, Scalia MJ. A cross-sectional study of the prevalence of cognitive and physical symptoms during long-term antidepressant treatment. J Clin Psychiatry. 2006;67:1754-1759.
Reinblatt SP, Riddle MA. Selective serotonin reuptake inhibitor-induced apathy: a pediatric case series. Journal of Child & Adolescent Psychopharmacology. 2006;16(1-2):227-233.
Goodwin GM, Price J, De Bodinat C, Laredo J. Emotional blunting with antidepressant treatments: A survey among depressed patients. J Affect Disord. 2017;221:31-35. Epub 2017 Jun 6. https://doi.org/10.1016/j.jad.2017.05.048
Price J, Cole V, Goodwin GM. Emotional side-effects of selective serotonin reuptake inhibitors: qualitative study. Br J Psychiatry. 2009;195(3):211-217. https://www.researchgate.net/publication/277899485_Antidepressant_induced_excessive_yawning_and_indiference https://doi.org/10.1192/bjp.bp.108.051110
Vertogradova OP, Koshkin KA. Apathetic depression: structure and dynamics. Social and Clinical Psychiatry. 2010;20(2):26-32. (In Russ.)
Maller O. Amotivational syndrome in chronic schizophrenics. Neuropsychobiology. 1978;4(4):229-247. https://doi.org/10.1159/000117636
Landes AM, Sperry SD, Strauss ME, Geldmacher DS. Apathy in Alzheimers disease. Journal of the American Geriatrics Society. 2001;49(12):1700-1707. https://doi.org/10.1046/j.1532-5415.2001.49282.x
Robert P, Onyike CU, Leentjens AFG, Dujardin K, Aalten P, Starkstein S, Verhey FRJ, Yessavage J, Clement JP, Drapier D, Bayle F, Benoit M,Boyer P, Lorca PM, Thibaut F, Gauthier S, Grossberg G, Vellas B, Byrne J. Proposed diagnostic criteria for apathy in Alzheimer’s disease and other neuropsychiatric disorders. European Psychiatry. 2009;24(2):98-104.
Marin RS. Apathy: concept, cyndrome, neural mechanisms, and treatment. Semin Clin Neuropsychiatry. 1996;1:304-314.
Marin RS. Apathy: a neuropsychiatric syndrome. J Neuropsychiatry Clin Neurosci. 1991;3:243-254.
Reijnders JS, Leentjens AF. Diagnosis and assessment of psychopathological symptoms in Parkinson’s disease. Tijdschrift Voor Psychiatrie. 2010;53(9):679-684. PMID: 21898328.
Yuen GS, Gunning FM, Woods E, Klimstra SA, Hoptman MJ, Alexopoulos GS. Neuroanatomical correlates of apathy in late-life depression and antidepressant treatment response. Journal of Affective Disorders. 2014;166:179-186. https://doi.org/10.1016/j.jad.2014.05.008
Tunnard C, Whitehead D, Hurt C, Wahlund LO, Mecocci P, Tsolaki M, Vellas B, Spenger C, Kłoszewska I, Soininen H, Lovestone S, Simmons A. Apathy and cortical atrophy in Alzheimer’s disease. International Journal of Geriatric Psychiatry. 2011;26(7):741-748. https://doi.org/10.1002/gps.2603
Zamboni G, Huey ED, Krueger F, Nichelli PF, Grafman J. Apathy and disinhibition in frontotemporal dementia Insights into their neural correlates. Neurology. 2008;71(10):736-742. https://doi.org/10.1212/01.wnl.0000324920.96835.95
Massimo L, Powers C, Moore P, Vesely L, Avants B, Gee J, Libon DJ, Grossman M. Neuroanatomy of apathy and disinhibition in frontotemporal lobar degeneration. Dementia and Geriatric Cognitive Disorders. 2009;27(1):96-104. https://doi.org/10.1159/000194658
Starkstein SE, Mizrahi R, Capizzano AA, Acion L, Brockman S, Power BD. Neuroimaging correlates of apathy and depression in Alzheimer’s disease. The Journal of Neuropsychiatry and Clinical Neurosciences. 2009;21(3):259-265. https://doi.org/10.1176/appi.neuropsych.21.3.259
Lavretsky H, Zheng L,Weiner MW, Mungas D, Reed B, Kramer JH, Jagust W, Chui H, Macket WJ. The MRI brain correlates of depressed mood,anhedonia, apathy, and anergia in older adults with and without cognitive impairment or dementia. International Journal of Geriatric Psychiatry. 2008;23(10):1040-1050. https://doi.org/10.1002/gps.2030
Grool AM, Geerlings MI, Sigurdsson S, Eiriksdottir G, Jonsson PV, Garcia ME, Siggeirsdottir K, Harris TB, Sigmundsson T, Gudnason V, Launer LJ. Structural MRI correlates of apathy symptoms in older persons without dementia AGES-Reykjavik Study. Neurology. 2014;82(18):1628-1635. https://doi.org/10.1212/WNL.0000000000000378
Groeneweg-Koolhoven I, Ploeg M, Comijs HC, Wjh Penninx B, van der Mast RC, Schoevers RA, Rhebergen D, Exel EV. Apathy in early and late-life depression. J Affect Disord. 2017;223:76-81. https://doi.org/10.1016/j.jad.2017.07.022
Ishii Sh, Weintraub N, Mervis J. Apathy: a common psychiatric syndrom in the elderly. J Am Med Dir Assoc. 2009;10:381-393.
Tekin S, Mega MS, Masterman DM, Chow T, Garakian J, Vinters HV, Cummings JL. Orbitofrontal and anterior cingulate cortex neurofibrillary tangl burden is assotiated with agitation in Alzheimer disease. Ann Neurol. 2001;49:355-361.
Stanton BR, Leigh PN, Howard RJ, Barker GJ, Brown RJ. Behavioural and emotional symptoms of apathy are associated with distinct patterns of brain atrophy in neurodegenerative disorders. Journal of Neurology. 2013;260(10):2481-2490. https://doi.org/10.1007/s00415-013-6989-9
Price J, Cole V, Goodwin GM. Emotional side-effects of selective serotonin reuptake inhibitors: qualitative study. Br J Psychiatry. 2009;195(3):211-217. https://doi.org/10.1192/bjp.bp.108.051110
Opbroek A, Delgado PL, Laukes C, McGahuey C, Katsanis J, Moreno FA, Manber R. Emotional blunting associated with SSRI-induced sexual dysfunction. Do SSRIs inhibit emotional responses? Int J Neuropsychopharmacol. 2002;5(2):147-151.
Garland EJ, Baerg EA. Amotivational syndrome associated with selective serotonin reuptake inhibitors in children and adolescents. J Child Adolesc Psychopharmacol. 2001;11:181-186.
Bernard WJ, Makela EH, Latocha MJ. SSSRI-induced apathy syndrome: a clinical review. J Psychiatrc Pract. 2004;10:196-199.
Goodwin GM, Price J, De Bodinat C, Laredo J. Emotional blunting with antidepressant treatments: A survey among depressed patients. J Affect Disord. 2017;221:31-35. https://doi.org/10.1016/j.jad.2017.05.048
De Deurwaerdère P, Di Giovanni G. Serotonergic modulation of the activity of mesencephalic dopaminergic systems: Therapeutic implications. Prog Neurobiol. 2017;151:175-236.
Wise RA. Forebrain substrates of reward and motivation. J Comp Neurol. 2005;493(1):115-121.
Callegari I, Mattei C, Benassi F, Krueger F, Grafman J, Yaldizli O, Sassos D, Massucco D, Scialo C, Amore M, Cocito L, Emberti Gialloreti L, Pardini M. Agomelatine improves apathy in frontotemporal dementia. Neurodegener Dis. 2016;16(5-6):352-356.
Padala PR, Padala K, Monga V, Ramirez D. Reversal of SSRI-associated apathy syndrome by discontinuation of therapy. Annals of Pharmacotherapy. 2012;46(3):8.
Garland EJ, Baerg EA. Amotivational syndrome associated with selective serotonin reuptake inhibitors in children and adolescents. J Child Adolesc Psychopharmacol. 2001;11:181-186.
Yamauchi M, Imanishi T, Koyama T. A combination of mirtazapine and milnacipran augments the extracellular levels of monoamines in the rat brain. Neuropharmacology. 2012;62(7):2278-2287. Epub 2012 Feb 4. https://doi.org/10.1016/j.neuropharm.2012.01.024
Nagomi T, Takano H, Arakawa R, Ichimiya T. Occupancy of serotonin and norepinephrine transporter by milnacipran in patients with major depressive disorder: a positron emission tomography study with [11C]DASB and (S,S)-[18F]FMeNER-D2. International Journal of Neuropsychopharmacology 2013;16:937-943.
Sechter D, Vandel P, Weiller E, Pezous N, Cabanac F, Tournoux A. A comparative study of milnacipran and paroxetine in outpatients with major depression. J Affect Disord. 2004;83(2-3):233-236. https://doi.org/10.1016/j.jad.2004.07.002
Chang TT, Lêng CH, Wu JY, Lee SY, Wang YS, Chen YC, Lu RB. Lower side effects of milnacipran than paroxetine in the treatment of major depression disorder among Han Chinese in Taiwan. Chin J Physiol. 2008;51(6):387-393.
Ueda H, Takashi H, Mayumi K. Effect of paroxetine and milnacipran on social adaptation in depressed patients (in Japanese). Presented at the 15th Japan Society for Clinical and Neuropsychiatric Pharmacology meeting. Tokyo. 2005.
Aleksandrovskij YuA, Avedisova AS, Yastrebov DV, Fajzulloev AZ, Kosenko VG, Smolenko LF, Glazunova TI, Karagezyan EA, Nabirkin GA, Boev IV, Boev OI, Yakshin VA, Sadovnichij KS. Effektivnost’ terapii preparatom Iksel rasstrojstv adaptacii u lic s narushennymi social’nymi svyazyami. Psihiatriya i Psihofarmakoterapiya im. P.B. Gannushkina. 2003;06:251-254. (In Russ.)
Chuhlovina ML, Chuhlovin AA. Evaluation of clinical manifestations and treatment of post-stroke depression in young patients with ischemic stroke. Zhurnal Nevrologii i Psihiatrii. 2018;03:52-55. (In Russ.)
Puozzo C, Hermann P, Chassard D. Lack of pharmacokinetic interaction when switching from fluoxetine to milnacipran. International Clinical Psychopharmacology. 2006;21(3):153-158.
Rouillon F, Berdeaux G, Bisserbe JC, Warner B, Mesbah M, Smadja C, Chwalow J. Prevention of recurrent depressive episodes with milnacipran: consequences on quality of life. J Affect Disord. 2000;58:171-180.
Baldwin D, Moreno RA, Briley M. Resolution of sexual dysfunction during acute treatment of major depression with milnacipran. Hum Psychopharmacol. 2008;23(6):527-532. https://doi.org/10.1002/hup.955
Kasper S, Pail G. Milnacipran: a unique antidepressant? Neuropsychiatr Dis Treat. 2010;6:23-31.
Serretti A, Calati R, Goracci A, Di Simplicio M, Castrogiovanni P, De Ronchi D. Antidepressants in healthy subjects: what are the psychotropic/psychological effects? Eur Neuropsychopharmacol. 2010;20(7):433-453.